重症肌无力
川东北74
免疫学
转录组
生物
医学
计算生物学
主要组织相容性复合体
MHC II级
抗原
遗传学
基因表达
基因
作者
Paula Terroba-Navajas,I‐Na Lu,Isaak Quast,Michael Heming,Christian W. Keller,Lennard Ostendorf,Anja E. Hauser,Ronja Mothes,Helena Radbruch,Frauke Stascheit,Andreas Meisel,Heinz Wiendl,Gerd Meyer zu Hörste,Nick Willcox,Jan D. Lünemann
标识
DOI:10.1212/nxi.0000000000200384
摘要
Myasthenia gravis (MG) is an autoimmune disease most frequently caused by autoantibodies (auto-Abs) against the acetylcholine receptor (AChR) located at the neuromuscular junction. Thymic follicular hyperplasia is present in most of the patients with early-onset AChR-Ab+ MG (EOMG), but its cellular and molecular drivers and development remain poorly understood. We constructed a single cell-based transcriptional profile of lymphoid cell types in thymi from 11 immunotherapy-naïve patients with EOMG. Multiplex histology and ELISA were used to determine migration inhibitory factor (MIF) levels. Within EOMG thymi, we consistently observed 6 distinct clusters of B-cell populations maturing toward germinal center (GC)-associated and Ab-secreting cells, featuring prominent GC activity, as indicated by substantial clonal expansions and cycling B-cell subsets. Cell-cell interactome predictions identified strong interactions between T cells and GC-associated and memory B cells, dominated by B-cell prosurvival signaling through the MIF-CD74 axis. Multiplex histology confirmed abundant expression of CD74 in MG thymic B cells. Circulating MIF levels in EOMG correlated with higher disease severity as assessed by Myasthenia Gravis Foundation of America status. Our data not only illustrate and define hyperplastic thymic niches in MG as favorable environments for pathogenic B-cell proliferation, maturation, and persistence but also suggest that the MIF-CD74 axis should be investigated for potential novel therapeutic targeting in EOMG.
科研通智能强力驱动
Strongly Powered by AbleSci AI